Humanwell Healthcare insists on R&D as the guide
Humanwell Healthcare insists on R&D as the guide, and is at the forefront of R&D investment and new drug R&D progress among domestic pharmaceutical enterprises, and is committed to building a first-class platform for R&D and industrialization of new drugs in China.
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Consumer Discretionary, Industrials
Tech for Global, Globalization Footprints of the Established and the New
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM